Theragnostics has signed a global licensing agreement with Advanced Accelerator Applications (AAA) to develop and commercialize gallium-68 (Ga-68) one-step PET radiopharmaceuticals.
Theragnostics will receive an upfront payment and will be eligible for future royalties on sales of resulting products under the agreement terms. AAA, a Novartis company, has exclusive rights to commercialize PET radiopharmaceuticals developed under the licensed patent.
The goal is for the technology platform being developed to enable the production of Ga-68 radiopharmaceuticals in a single multidose vial in one step, which has the potential to diagnose a broad range of cancers, company leaders said.
